ACST Share Price | Acasti Pharma, Inc. Stock Analysis & Recommendation

Q: How big is Acasti Pharma, Inc.?

Market Cap: As of Jun 18, Acasti Pharma, Inc. has a market capitalization of 39.23 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Acasti Pharma, Inc. reported net sales of 0.00 million and a net profit of -13.38 million.Balance Sheet Snapshot: As of Mar 24, the company reported shareholder's funds of 61.74 million and total assets of 73.30 million.

Q: What does Acasti Pharma, Inc. do?

Overview: Acasti Pharma, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -4 Million (Quarterly Results - Dec 2024) Market cap: USD 39.23 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.21 Return on Equity: -24.78% Price to Book: 0.75Contact Details: Address: 3009, BOUL. DE LA CONCORDE EAST, SUITE 102 LAVAL QC : H7E 2B5 Tel: 1 450 6864555 Website: https://www.acastipharma.com/

Q: Who are in the management team of Acasti Pharma, Inc.?

As of March 2022, the management team of Acasti Pharma, Inc. includes Dr. Roderick Carter, who serves as the Independent Chairman of the Board, and Ms. Janelle D'Alvise, who is the President, Chief Executive Officer, and a Director. Additionally, the board features Mr. Jean-Marie Canan and Mr. Donald Olds, both serving as Independent Directors.

Q: Is Acasti Pharma, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Acasti Pharma, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a mildly bullish stance on the weekly and a bullish stance on the monthly. However, the KST shows a mildly bearish signal on both weekly and monthly time frames. The daily moving averages are mildly bullish, and the OBV is bullish on the weekly but shows no trend on the monthly.In terms of performance, Acasti Pharma has underperformed the S&P 500 across multiple periods, with a year-to-date return of -16.58% compared to the S&P 500's 12.22%, and a 5-year return of -69.95% versus the S&P 500's 96.61%. Overall, the current technical stance is mildly bullish, but the stock's performance relative to the benchmark indicates significant weakness.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

102.1 k

Shareholding (Dec 2025)

FII

0.11%

Held by 7 FIIs

DII

97.3%

Held by 3 DIIs

Promoter

0.00%

How big is Acasti Pharma, Inc.?

22-Jun-2025

As of Jun 18, Acasti Pharma, Inc. has a market capitalization of 39.23 million, with net sales of 0.00 million and a net profit of -13.38 million over the latest four quarters. The company reported shareholder's funds of 61.74 million and total assets of 73.30 million as of Mar 24.

View full answer

What does Acasti Pharma, Inc. do?

22-Jun-2025

Acasti Pharma, Inc. is a biopharmaceutical company specializing in the development of prescription drugs using omega-3 fatty acids from krill oil. It operates as a micro-cap company with a market cap of approximately $39.23 million and reported a net profit loss of $4 million in December 2024.

View full answer

Who are in the management team of Acasti Pharma, Inc.?

22-Jun-2025

As of March 2022, Acasti Pharma, Inc.'s management team includes Dr. Roderick Carter as Independent Chairman, Ms. Janelle D'Alvise as President and CEO, and Independent Directors Mr. Jean-Marie Canan and Mr. Donald Olds.

View full answer

Is Acasti Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Acasti Pharma's technical trend is mildly bullish, with mixed indicators, but it has significantly underperformed the S&P 500, showing a year-to-date return of -16.58% compared to the S&P's 12.22%.

View full answer

Compare Acasti Pharma, Inc. with Similar Stocks

Alzamend Neuro, Inc.Vincerx Pharma, Inc.AIM ImmunoTech, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 68 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.29

Return on Equity

-14.67%

Price to Book

1.05

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

31.75%

6 Months

43.23%

1 Year

75.49%

2 Years

30.59%

3 Years

932.56%

4 Years

252.38%

5 Years

-84.63%

Acasti Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-1.65%

EBIT Growth (5y)

4.56%

EBIT to Interest (avg)

-19.80

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.33

Sales to Capital Employed (avg)

0.00

Tax Ratio

25.06%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

27.99%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.05

EV to EBIT

-4.42

EV to EBITDA

-4.42

EV to Capital Employed

1.08

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-24.34%

ROE (Latest)

-14.67%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 1 Schemes (2.59%)

Foreign Institutions

Held by 7 Foreign Institutions (0.11%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 45.24% vs -75.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.40",
          "val2": "-3.70",
          "chgp": "35.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-1.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.30",
          "val2": "-4.20",
          "chgp": "45.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 25.58% vs 69.58% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.70",
          "val2": "-11.30",
          "chgp": "-47.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.20",
          "val2": "-4.20",
          "chgp": "176.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.60",
          "val2": "-12.90",
          "chgp": "25.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.40

-3.70

35.14%

Interest

0.00

Exceptional Items

-0.00

-1.20

100.00%

Consolidate Net Profit

-2.30

-4.20

45.24%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 45.24% vs -75.00% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-16.70

-11.30

-47.79%

Interest

0.00

Exceptional Items

3.20

-4.20

176.19%

Consolidate Net Profit

-9.60

-12.90

25.58%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 25.58% vs 69.58% in Mar 2024

All Annual Results

Company CV

About Acasti Pharma, Inc.

Acasti Pharma, Inc.

Pharmaceuticals & Biotechnology

Acasti Pharma Inc. is a biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. It is developing a cardiovascular drug, CaPre (omega-3 phospholipid) for the treatment of hypertriglyceridemia. CaPre is a krill oil derived mixture containing polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). CaPre is designed to reduce triglycerides while also potentially providing beneficial effects on low-density lipoprotein (LDL) cholesterol (LDL-C) and high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with severe hypertriglyceridemia.

Company Coordinates

Company Details

3009, BOUL. DE LA CONCORDE EAST, SUITE 102 LAVAL QC : H7E 2B5

Tel: 1 450 6864555

https://www.acastipharma.com/

Registrar Details